

Calcibel Forte, 380/60/50 mg/ml Solution for Infusion for Horses, Cattle, Sheep, Goats and Pigs

Authorised

- Calcium gluconate
- Magnesium chloride hexahydrate
- Boric acid

Product identification

Medicine name:

Calcibel Forte, 380/60/50 mg/ml solution for infusion for horses, cattle, sheep, goats and pigs

Calcibel Forte, 380/60/50 mg/ml Solution for Infusion for Horses, Cattle, Sheep, Goats and Pigs

Active substance:

Calcium gluconate

Magnesium chloride hexahydrate

Boric acid

Target species:

Horse

Cattle

Sheep

Goat

Pig

Route of administration:

Intravenous use

Product details

Active substance and strength:

Calcium gluconate

380.00 milligram(s) / 1.00 millilitre(s)

Magnesium chloride hexahydrate

60.00 milligram(s) / 1.00 millilitre(s)

Boric acid

50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for infusion

Withdrawal period by route of administration:**Intravenous use:**

-

Horse

- Milk. 0 hour

- Meat and offal. 0 day

-

Cattle

- Milk. 0 hour

- Meat and offal. 0 day

-

Sheep

- Milk. 0 hour

- Meat and offal. 0 day

-

Goat

- Milk. 0 hour
- Meat and offal. 0 day

-

Pig

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA12AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

United Kingdom (Northern Ireland)

Package description:

Plastic Bottle 12 x 500.0 millilitre(s)

Plastic Bottle 1 x 500.0 millilitre(s)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Bela-Pharm GmbH & Co. KG

Marketing authorisation date:

2/11/2021

Manufacturing sites for batch release:

Bela-Pharm GmbH & Co. KG

Responsible authority:

The Veterinary Medicines Directorate

Authorisation number:

Vm 41816/4005

Date of authorisation status change:

27/06/2024

Reference member state:

Czechia

Procedure number:

CZ/V/0170/001

Concerned member states:

Austria Cyprus Denmark Estonia Finland Greece Hungary Iceland Ireland
Italy Latvia Lithuania Poland Portugal Romania Slovakia Slovenia Spain
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet